What Is New With Acne in October 2026? Latest FDA and dermatology sources and Key Takeaways

The biggest acne news in October 2026 is long-term data for an experimental pill and easier store access to a proven combination gel. Oral denifanstat kept reducing lesions through 52 weeks in a Phase 3 extension, while Differin Epiduo Acne Gel moved from prescription to over-the-counter. Sagimet reported the 52-week extension results on Sept.

30, 2026. Galderma received FDA approval for the prescription-to-OTC switch on May 22, 2026. Denifanstat is a fatty-acid synthase inhibitor, an oral drug that targets sebum production.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Official resources:

Read the official notice from FDA — Use this primary source to verify the official announcement.
Register through Biospace’s official page — Use this page to review requirements and register directly.

What did the 52-week denifanstat results show?
Can U.S. patients get denifanstat now?
What changed at the drugstore?
Are benzoyl peroxide products safe to keep using?
What should you use right now?

What did the 52-week denifanstat results show?

Sagimet announced full 52-week open-label extension results for denifanstat in moderate-to-severe acne vulgaris. Treatment success reached 56.7% and mean total-lesion reduction reached 71.8%, with continued improvement over time. The data came from license partner Ascletis and its ASC40-304 trial in China. Dermatology Times reported on Oct.

1, 2026 that results were presented at the EADV Congress in Vienna, held Sept. 30-Oct. 3, 2026, and that patients who crossed over from placebo reached success rates similar to patients treated from the start Dermatology Times report. That catch-up pattern matters for readers with stubborn acne. It suggests longer treatment, not early response alone, drives benefit.

Can U.S. patients get denifanstat now?

No. Clinical Trial Vanguard reported that FDA issued a Study May Proceed letter on Aug. 13, 2026 for a U.S. Phase 3 trial of oral denifanstat in moderate-to-severe acne. The source described it as a first novel oral sebum-targeting mechanism in decades.

Sagimet said on Aug. 25, 2026 through BioSpace that its U.S. Phase 3 AURORA trial remains on track to enroll its first patient in Q4 2026. U.S. efficacy is therefore not yet proven. Anyone interested should watch trial enrollment and discuss current prescription options with a dermatologist in the meantime.

What changed at the drugstore?

Galderma received FDA approval on May 22, 2026 to switch Differin Epiduo Acne Gel from prescription to OTC use in ages 12 and older. The product combines adapalene 0.1% plus benzoyl peroxide 2.5%, expanding nonprescription combination retinoid access the FDA approval notice.

For shoppers, that means one fewer prescription barrier for a fixed-dose retinoid combination. It does not change who the product fits.

Age 12 and older with acne that suits a retinoid plus benzoyl peroxide approach
People who prefer a store-bought combination rather than separate prescriptions
Anyone who should still check with a pharmacist about use, irritation, and sun protection

Are benzoyl peroxide products safe to keep using?

FDA testing of 95 benzoyl-peroxide products found more than 90% had undetectable or extremely low benzene. FDA said only a limited number were recalled at retail the FDA benzene findings. FDA also noted benzoyl peroxide can degrade to benzene with heat or improper storage.

That storage point gives a clear action. Keep benzoyl peroxide in a cool, dry place, avoid hot cars and heaters, and replace old tubes. BeautyMatter reported that on Sept. 15, 2026 Judge Analisa Torres dismissed claims that L'Oreal's CeraVe and La Roche-Posay benzoyl-peroxide products required benzene warnings, holding that FDA's acne monograph treats benzoyl peroxide as safe and effective without such warning.

What should you use right now?

The American Academy of Dermatology guidelines, reported via Newswise and JAAD and current from 2024, strongly recommend topical benzoyl peroxide, retinoids and antibiotics, fixed-dose combinations, and oral isotretinoin for severe acne. They conditionally recommend clascoterone, sarecycline, and hormonal options, partly limited by high cost and access.

That mix favors simple, proven routines while newer pills finish testing. A fixed-dose combination can reduce layering and missed doses. If cost blocks a newer option, ask a clinician about a guideline-backed generic alternative.